10-YEAR CARDIOVASCULAR RISK REDUCTION, EFFICACY AND SAFETY OF ALIROCUMAB AND EVOLOCUMAB, IN ADDITION TO MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY: POST-COMMERCIALIZATION STUDY